DAS181 Treatment of Severe Lower Respiratory Tract Parainfluenza Virus Infection in Immunocompromised Patients: A Phase 2 Randomized, Placebo-Controlled Study
Resource type
Journal Article
Authors/contributors
- Chemaly, Roy F (Author)
- Marty, Francisco M (Author)
- Wolfe, Cameron R (Author)
- Lawrence, Steven J (Author)
- Dadwal, Sanjeet (Author)
- Soave, Rosemary (Author)
- Farthing, Jason (Author)
- Hawley, Stephen (Author)
- Montanez, Paul (Author)
- Hwang, Jimmy (Author)
- Ho, Jennifer Hui-Chun (Author)
- Lewis, Stanley (Author)
- Wang, George (Author)
- Boeckh, Michael (Author)
Title
DAS181 Treatment of Severe Lower Respiratory Tract Parainfluenza Virus Infection in Immunocompromised Patients: A Phase 2 Randomized, Placebo-Controlled Study
Abstract
Immunocompromised adults with severe parainfluenza received nebulized DAS181 or placebo for up to 10 days. The primary endpoint was not met, but a subgroup of severely immunocompromised patients experienced a faster return to room air by day 28 (P = .012).
Publication
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Date
2021-2-11
Volume
73
Issue
3
Pages
e773-e781
Journal Abbr
Clin Infect Dis
Accessed
6/7/22, 8:32 AM
ISSN
1058-4838
Short Title
DAS181 Treatment of Severe Lower Respiratory Tract Parainfluenza Virus Infection in Immunocompromised Patients
Library Catalog
PubMed Central
Extra
PMID: 33569576
PMCID: PMC8326557
Citation
Chemaly, R. F., Marty, F. M., Wolfe, C. R., Lawrence, S. J., Dadwal, S., Soave, R., Farthing, J., Hawley, S., Montanez, P., Hwang, J., Ho, J. H.-C., Lewis, S., Wang, G., & Boeckh, M. (2021). DAS181 Treatment of Severe Lower Respiratory Tract Parainfluenza Virus Infection in Immunocompromised Patients: A Phase 2 Randomized, Placebo-Controlled Study. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, 73(3), e773–e781. https://doi.org/10.1093/cid/ciab113
Link to this record